

Banu K Arun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5017402/publications.pdf>

Version: 2024-02-01

154
papers

11,867
citations

57631

44
h-index

30010

103
g-index

157
all docs

157
docs citations

157
times ranked

16772
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. <i>Contemporary Clinical Trials</i> , 2022, 113, 106662.	0.8	1
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
3	Clinical outcomes and Oncotype DX Breast Recurrence Score [®] in early-stage <sc>BRCA</sc>-associated hormone receptor-positive breast cancer. <i>Cancer Medicine</i> , 2022, 11, 1474-1483.	1.3	5
4	Helping Patients Understand and Cope with BRCA Mutations. <i>Current Oncology Reports</i> , 2022, 24, 733-740.	1.8	4
5	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	1.7	4
6	Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 46.	2.3	10
7	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	2.3	3
8	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.	2.1	5
9	Perceptions of provider's epistemic authority in response to variant of uncertain significance-related recommendations. <i>Journal of Genetic Counseling</i> , 2021, 30, 513-521.	0.9	1
10	Patient characteristics associated with sleep disturbance in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 2601-2611.	1.0	18
11	Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 303-307.	0.6	9
12	Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication. <i>Journal of Community Genetics</i> , 2021, 12, 439-447.	0.5	3
13	Breast tumours maintain a reservoir of subclonal diversity during expansion. <i>Nature</i> , 2021, 592, 302-308.	13.7	145
14	Health care professionals' attitudes toward cancer gene panel testing. <i>Breast Journal</i> , 2021, 27, 499-500.	0.4	1
15	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
16	Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. <i>Cancers</i> , 2021, 13, 2050.	1.7	2
17	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. <i>Cancers</i> , 2021, 13, 1656.	1.7	16
18	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. <i>Cancer</i> , 2021, 127, 3605-3613.	2.0	7
20	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
21	Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. <i>Cancer</i> , 2021, , .	2.0	5
22	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. <i>Oncologist</i> , 2021, 26, e2086-e2089.	1.9	4
23	Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2-advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	1.3	10
24	Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	1
25	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-394.	0.8	151
26	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
27	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
28	A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia. <i>Molecular Cell</i> , 2020, 80, 1013-1024.e6.	4.5	29
29	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	0.4	3
30	Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. <i>Annals of Surgical Oncology</i> , 2020, 27, 4613-4621.	0.7	13
31	Impact of a Genetic Evaluation Initiative to Increase Access to Genetic Services for Adolescent and Young Adults at a Tertiary Cancer Hospital. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 296-302.	0.7	1
32	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	5.1	207
33	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
34	Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. <i>Cancer Prevention Research</i> , 2020, 13, 795-802.	0.7	3
35	Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. <i>Breast Journal</i> , 2020, 26, 1572-1582.	0.4	6
36	Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 5.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa002.	1.4	8
38	Should abbreviated breast MRI be compliant with American College of Radiology requirements for MRI accreditation?. Magnetic Resonance Imaging, 2020, 72, 87-94.	1.0	4
39	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
40	Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. Supportive Care in Cancer, 2020, 28, 5821-5832.	1.0	15
41	Multigene panel testing results in patients with multiple breast cancer primaries. Breast Journal, 2020, 26, 1337-1342.	0.4	6
42	Establishing a Program for Young Women at High Risk for Breast Cancer. , 2020, , 35-46.		0
43	Polygenic Risk Scores in Breast Cancer. Current Breast Cancer Reports, 2019, 11, 117-122.	0.5	0
44	EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses <i>BRCA1</i> -mutated breast cancer. Nanomedicine, 2019, 14, 2315-2338.	1.7	17
45	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast Journal, 2019, 25, 575-577.	0.4	3
46	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
47	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.4	69
48	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
49	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
50	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment, 2019, 176, 545-556.	1.1	16
51	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
52	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
53	Epidemiology, Risk Factors, and Prevention. , 2019, , 39-61.		1
54	Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Research and Treatment, 2018, 170, 101-109.	1.1	18

#	ARTICLE	IF	CITATIONS
55	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	2.0	11
56	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
57	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 299-306.	1.2	16
58	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. <i>Cancer</i> , 2018, 124, 866-866.	2.0	0
59	The changing landscape of hereditary cancer genetic testing. <i>Cancer</i> , 2018, 124, 664-666.	2.0	2
60	Validation of a personalized risk prediction model for contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 415-423.	1.1	19
61	<i>BRCA</i> mutations in women with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 466-474.	2.0	14
62	Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. <i>Cancer</i> , 2018, 124, 36-45.	2.0	70
63	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing <i>c-kit</i> or <i>PDGFR-β</i> . <i>Investigational New Drugs</i> , 2018, 36, 1103-1109.	1.2	13
64	Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings. <i>Journal of Genetic Counseling</i> , 2018, 27, 1482-1496.	0.9	11
65	Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 518-524.	2.3	14
66	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
67	Germline <i>BRCA1/BRCA2</i> mutations among high risk breast cancer patients in Jordan. <i>BMC Cancer</i> , 2018, 18, 152.	1.1	27
68	Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. <i>Cancer Medicine</i> , 2018, 7, 2718-2726.	1.3	25
69	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1207.	3.4	56
70	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710
71	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	1.4	58
72	Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. <i>Oncologist</i> , 2017, 22, 655-666.	1.9	7

#	ARTICLE	IF	CITATIONS
73	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
74	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€‘AJCC TNM staging system. <i>Lancet Oncology</i> , The, 2017, 18, e228-e232.	5.1	74
75	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , 2017, 23, 4066-4076.	3.2	87
76	BRCA mutation genetic testing implications in the United States. <i>Breast</i> , 2017, 31, 224-232.	0.9	41
77	Association between weight gain during adjuvant chemotherapy for earlyâ€‘stage breast cancer and survival outcomes. <i>Cancer Medicine</i> , 2017, 6, 2515-2522.	1.3	28
78	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
79	Targeting Aberrant p70S6K Activation for Estrogen Receptorâ€‘Negative Breast Cancer Prevention. <i>Cancer Prevention Research</i> , 2017, 10, 641-650.	0.7	4
80	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
81	Active Disclosure of Secondary Germline Findings to Deceased Research Participantsâ€™ Personal Representatives: Process and Outcomes. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	3
82	Medical Management of Breast Cancer in BRCA Mutation Carriers. , 2017, , 135-150.		0
83	Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. <i>Frontiers in Genetics</i> , 2016, 7, 71.	1.1	5
84	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
85	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	1.1	26
86	Cancer Incidence in First- and Second-Degree Relatives of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Oncologist</i> , 2016, 21, 869-874.	1.9	41
87	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
88	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 67-77.	1.1	16
89	A two-stage approach to genetic risk assessment in primary care. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 375-383.	1.1	13
90	Rates of BRCA1/2 mutation testing among young survivors of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 165-173.	1.1	16

#	ARTICLE	IF	CITATIONS
91	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
92	<i>Epidemiology, Risk Factors, and Prevention.</i> , 2016, , 57-87.		1
93	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. <i>American Journal of Cancer Research</i> , 2016, 6, 981-95.	1.4	4
94	High incidence of germline <i>BRCA</i> mutation in patients with ER low α positive/PR low α positive/HER α 2 <i>neu</i> negative tumors. <i>Cancer</i> , 2015, 121, 3422-3427.	2.0	78
95	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
96	Reply to <i>BRCA2</i> α associated pancreatic cancer and current screening guidelines. <i>Cancer</i> , 2015, 121, 3047-3047.	2.0	0
97	Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 784-791.	0.4	13
98	Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are <i>BRCA</i> -Negative. <i>Journal of Cancer</i> , 2015, 6, 610-615.	1.2	8
99	Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict <i>BRCA</i> Mutation Status of Patients with Invasive Breast Cancer. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S29716.	3.6	11
100	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
101	The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in <i>BRCA1</i> and <i>BRCA2</i> mutant breast cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 262-268.	1.4	81
102	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416.	1.1	68
103	BRCAPRO 6.0 Model Validation in Male Patients Presenting for <i>BRCA</i> Testing. <i>Oncologist</i> , 2015, 20, 593-597.	1.9	13
104	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. <i>Cancer Research</i> , 2015, 75, 4863-4875.	0.4	44
105	Genotype-Phenotype Correlations by Ethnicity and Mutation Location in <i>BRCA</i> Mutation Carriers. <i>Breast Journal</i> , 2015, 21, 260-267.	0.4	21
106	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015, 33, 3660-3667.	0.8	603
107	Cancers associated with $\langle scp \rangle \langle i \rangle BRCA \langle /i \rangle \langle /scp \rangle \langle i \rangle 1 \langle /i \rangle$ and $\langle scp \rangle \langle i \rangle BRCA \langle /i \rangle \langle /scp \rangle \langle i \rangle 2 \langle /i \rangle$ mutations other than breast and ovarian. <i>Cancer</i> , 2015, 121, 269-275.	2.0	407
108	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. <i>Journal of Cancer</i> , 2014, 5, 351-359.	1.2	4

#	ARTICLE	IF	CITATIONS
109	Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis. <i>Oncologist</i> , 2014, 19, 797-804.	1.9	21
110	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
111	Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. <i>Breast</i> , 2014, 23, 770-774.	0.9	25
112	Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. <i>Familial Cancer</i> , 2014, 13, 291-299.	0.9	56
113	Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. <i>Annals of Surgical Oncology</i> , 2014, 21, 3466-3472.	0.7	22
114	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
115	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
116	USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 10-17.	1.0	39
117	Establishing a Program for Individuals at High Risk for Breast Cancer. <i>Journal of Cancer</i> , 2013, 4, 433-446.	1.2	14
118	Ductal carcinoma <i>in situ</i> : how should we treat it?. <i>Breast Cancer Management</i> , 2013, 2, 245-256.	0.2	0
119	Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer. <i>Cancer Prevention Research</i> , 2012, 5, 276-282.	0.7	6
120	Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. <i>Annals of Surgical Oncology</i> , 2012, 19, 3777-3784.	0.7	67
121	Predictive factors for <i>BRCA1</i> / <i>BRCA2</i> mutations in women with ductal carcinoma in situ. <i>Cancer</i> , 2012, 118, 1515-1522.	2.0	23
122	Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. <i>Hereditary Genetics: Current Research</i> , 2012, 01, .	0.1	2
123	Response to Neoadjuvant Systemic Therapy for Breast Cancer in <i>BRCA</i> Mutation Carriers and Noncarriers: A Single-Institution Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 3739-3746.	0.8	151
124	Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 145-153.	1.1	96
125	Satisfaction with ovarian carcinoma risk reduction strategies among women at high risk for breast and ovarian carcinoma. <i>Cancer</i> , 2011, 117, 2659-2667.	2.0	22
126	Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious <i>BRCA</i> mutations at high risk of breast cancer. <i>Cancer</i> , 2011, 117, 3900-3907.	2.0	79

#	ARTICLE	IF	CITATIONS
127	Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without Câ€CSF in Locally Advanced Breast Cancer: Longâ€Term Results. <i>Oncologist</i> , 2011, 16, 1527-1534.	1.9	29
128	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1082-1089.	3.2	487
129	Breast Cancer Prevention Trials: Large and Small Trials. <i>Seminars in Oncology</i> , 2010, 37, 367-383.	0.8	18
130	Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. <i>Cancer Prevention Research</i> , 2010, 3, 1026-1034.	0.7	138
131	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , 2010, 376, 235-244.	6.3	1,584
132	Expanding the Criteria for <i>BRCA</i> Mutation Testing in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4214-4220.	0.8	120
133	Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. <i>Cancer Investigation</i> , 2010, 28, 554-559.	0.6	24
134	High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. <i>Cancer Prevention Research</i> , 2009, 2, 122-127.	0.7	33
135	Ductal Carcinoma in Situ: State of the Science and Roadmap to Advance the Field. <i>Journal of Clinical Oncology</i> , 2009, 27, 279-288.	0.8	151
136	Perception of screening and risk reduction surgeries in patients tested for a <i>BRCA</i> deleterious mutation. <i>Cancer</i> , 2009, 115, 1598-1604.	2.0	31
137	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. <i>BMC Cancer</i> , 2008, 8, 101.	1.1	22
138	Clinical and Pathologic Characteristics of Patients With <i>BRCA</i>-Positive and <i>BRCA</i>-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4282-4288.	0.8	535
139	Risk Management of Hereditary Breast Cancer. , 2008, , 93-105.		0
140	Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. <i>Clinical Cancer Research</i> , 2007, 13, 4943-4948.	3.2	27
141	Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. <i>Modern Pathology</i> , 2006, 19, 622-629.	2.9	25
142	Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing. <i>Cancer</i> , 2006, 107, 2745-2751.	2.0	61
143	Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. <i>Obstetrics and Gynecology</i> , 2006, 108, 515-520.	1.2	55
144	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancerâ€A Plan to Move Forward. <i>Clinical Cancer Research</i> , 2006, 12, 3661-3697.	3.2	263

#	ARTICLE	IF	CITATIONS
145	Women age ≥ 35 years with primary breast carcinoma. <i>Cancer</i> , 2005, 103, 2466-2472.	2.0	78
146	Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1681-1685.	1.1	24
147	Ductal Lavage and Risk Assessment of Breast Cancer. <i>Oncologist</i> , 2004, 9, 599-605.	1.9	5
148	The role of COX-2 inhibition in breast cancer treatment and prevention. <i>Seminars in Oncology</i> , 2004, 31, 22-29.	0.8	180
149	Contralateral prophylactic mastectomy. <i>Cancer</i> , 2004, 101, 1977-1986.	2.0	102
150	Correlation of bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. <i>Cancer</i> , 2003, 98, 2554-2559.	2.0	18
151	Management of women at high risk for breast cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1 Suppl 1, S71-7.	2.3	0
152	The search for the ideal SERM. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 681-691.	0.9	29
153	Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 491-505.	0.9	33
154	Endothelin Converting Enzyme-1 Expression in Endometrial Adenocarcinomas. <i>Cancer Investigation</i> , 2001, 19, 779-782.	0.6	10